BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20188676)

  • 21. Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites.
    Atre T; Robinson TM; Savransky T; Dutta S; Epstein JE; Bergmann-Leitner ES
    Malar J; 2019 May; 18(1):186. PubMed ID: 31142328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of Plasmodium knowlesi versus Plasmodium falciparum in the rhesus liver: implications for malaria vaccine studies in rhesus models.
    Shears MJ; Seilie AM; Kim Lee Sim B; Hoffman SL; Murphy SC
    Malar J; 2020 Aug; 19(1):313. PubMed ID: 32867784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal role for the circumsporozoite protein in the induction of sterile immunity by vaccination with live rodent malaria sporozoites.
    Mauduit M; Tewari R; Depinay N; Kayibanda M; Lallemand E; Chavatte JM; Snounou G; Rénia L; Grüner AC
    Infect Immun; 2010 May; 78(5):2182-8. PubMed ID: 20194600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites.
    Charoenvit Y; Mellouk S; Cole C; Bechara R; Leef MF; Sedegah M; Yuan LF; Robey FA; Beaudoin RL; Hoffman SL
    J Immunol; 1991 Feb; 146(3):1020-5. PubMed ID: 1988490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites.
    Sedegah M; Weiss WW; Hoffman SL
    Parasite Immunol; 2007 Nov; 29(11):559-65. PubMed ID: 17944745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-selecting circumsporozoite protein-based malaria vaccine: A comparison of malaria sporozoite challenge model.
    Amelia F; Iyori M; Emran TB; Yamamoto DS; Genshi K; Otsuka H; Onoue Y; Yusuf Y; Islam A; Yoshida S
    Parasite Immunol; 2019 May; 41(5):e12624. PubMed ID: 30883819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Plasmodium Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice.
    Vaughan AM; Sack BK; Dankwa D; Minkah N; Nguyen T; Cardamone H; Kappe SHI
    Infect Immun; 2018 May; 86(5):. PubMed ID: 29440367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites.
    van Schaijk BC; Ploemen IH; Annoura T; Vos MW; Foquet L; van Gemert GJ; Chevalley-Maurel S; van de Vegte-Bolmer M; Sajid M; Franetich JF; Lorthiois A; Leroux-Roels G; Meuleman P; Hermsen CC; Mazier D; Hoffman SL; Janse CJ; Khan SM; Sauerwein RW
    Elife; 2014 Nov; 3():. PubMed ID: 25407681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2.
    Nouatin O; Mengue JB; Dejon-Agobé JC; Fendel R; Ibáñez J; Ngoa UA; Edoa JR; Adégbité BR; Honkpéhédji YJ; Zinsou JF; Hounkpatin AB; Moutairou K; Homoet A; Esen M; Kreidenweiss A; Hoffman SL; Theisen M; Luty AJF; Lell B; Agnandji ST; Mombo-Ngoma G; Ramharter M; Kremsner P; Mordmüller B; Adegnika AA
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009361. PubMed ID: 34061838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.
    Calvo-Calle JM; Oliveira GA; Watta CO; Soverow J; Parra-Lopez C; Nardin EH
    Infect Immun; 2006 Dec; 74(12):6929-39. PubMed ID: 17030584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Live attenuated pre-erythrocytic malaria vaccines.
    Keitany GJ; Vignali M; Wang R
    Hum Vaccin Immunother; 2014; 10(10):2903-9. PubMed ID: 25483648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells.
    Tarun AS; Dumpit RF; Camargo N; Labaied M; Liu P; Takagi A; Wang R; Kappe SH
    J Infect Dis; 2007 Aug; 196(4):608-16. PubMed ID: 17624848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy.
    Leitner WW; Bergmann-Leitner ES; Angov E
    Malar J; 2010 May; 9():145. PubMed ID: 20507620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel approaches to whole sporozoite vaccination against malaria.
    Bijker EM; Borrmann S; Kappe SH; Mordmüller B; Sack BK; Khan SM
    Vaccine; 2015 Dec; 33(52):7462-8. PubMed ID: 26469716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine.
    Senkpeil L; Bhardwaj J; Little MR; Holla P; Upadhye A; Fusco EM; Swanson PA; Wiegand RE; Macklin MD; Bi K; Flynn BJ; Yamamoto A; Gaskin EL; Sather DN; Oblak AL; Simpson E; Gao H; Haining WN; Yates KB; Liu X; Murshedkar T; Richie TL; Sim BKL; Otieno K; Kariuki S; Xuei X; Liu Y; Polidoro RB; Hoffman SL; Oneko M; Steinhardt LC; Schmidt NW; Seder RA; Tran TM
    JCI Insight; 2024 Apr; 9(11):. PubMed ID: 38687615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.
    Charoenvit Y; Majam VF; Corradin G; Sacci JB; Wang R; Doolan DL; Jones TR; Abot E; Patarroyo ME; Guzman F; Hoffman SL
    Infect Immun; 1999 Nov; 67(11):5604-14. PubMed ID: 10531206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irradiated sporozoites prime mice to produce high antibody titres upon viable Plasmodium berghei sporozoite challenge, which act upon liver-stage development.
    Chatterjee S; Druilhe P; Wery M
    Parasitology; 1999 Mar; 118 ( Pt 3)():219-25. PubMed ID: 10205797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.
    Richie TL; Charoenvit Y; Wang R; Epstein JE; Hedstrom RC; Kumar S; Luke TC; Freilich DA; Aguiar JC; Sacci JB; Sedegah M; Nosek RA; De La Vega P; Berzins MP; Majam VF; Abot EN; Ganeshan H; Richie NO; Banania JG; Baraceros MF; Geter TG; Mere R; Bebris L; Limbach K; Hickey BW; Lanar DE; Ng J; Shi M; Hobart PM; Norman JA; Soisson LA; Hollingdale MR; Rogers WO; Doolan DL; Hoffman SL
    Hum Vaccin Immunother; 2012 Nov; 8(11):1564-84. PubMed ID: 23151451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.